American Society of Hirudotherapy

Desirudin

Recombinant hirudin variant — FDA-approved 2003 for prophylaxis of DVT after hip replacement surgery.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Desirudin7 kDa
Molecular weight (kilodaltons) of Desirudin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.
Page type
Compound profile
Evidence type
Clinical and regulatory evidence (FDA-approved derived drug)
Evidence level
FDA-cleared regulatory context
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding · Allergy / anaphylaxis

Clinical translation limit

Desirudin is a yeast-expressed recombinant hirudin drug, FDA-approved for DVT prophylaxis after hip replacement. Its clinical evidence base applies only to the recombinant drug; it does NOT extend to claims about whole medicinal-leech therapy.

Molecular Profile

Category
Anticoagulant
Evidence tier
Tier A — FDA-approved derivative
Molecular weight
6,964 Da
Source species
Recombinant (Saccharomyces cerevisiae)
Discovered
1995 · Novartis (later Canyon Pharmaceuticals)
PDB structures
1HUT
Derived FDA-approved drug
Iprivask / Revasc (FDA approved April 2003)

Biological Targets

  • → thrombin (Factor IIa)

Key Citations

  1. Eriksson BI et al. (1997), N Engl J Med · PMID 9358126

Related Anticoagulant Compounds

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.